Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer-Reference-Cited by-同舟云学术

Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer

Published:2022-02-17 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Alves Fátima R,Gil Lucia,Vasconcelos de Matos Leonor,Baleiras Ana,Vasques Carolina,Neves Maria Teresa,Ferreira André,Fontes-Sousa Mário,Miranda Helena,Martins Ana

Publisher

Cureus, Inc.

Subject

Aerospace Engineering

Reference22 articles.

1. HER2-low breast cancer: pathological and clinical landscape;Tarantino P;J Clin Oncol,2020

2. Dissecting the biological heterogeneity of HER2-positive breast cancer;Schettini F;Breast,2021

3. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions;Ferraro E;Breast Cancer Res,2021

4. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update;Wolff AC;J Clin Oncol,2018

5. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis;Schettini F;Cancer Treat Rev,2020

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis;Frontiers in Oncology;2024-08-29

2. HER2-Low Breast Cancer: Now and in the Future;Cancer Research and Treatment;2024-07-15

3. Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis;World Journal of Surgical Oncology;2024-04-20

4. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer;ESMO Open;2024-04

5. Insights Into the Emerging Entity of HER2‐Low Breast Cancer;International Journal of Breast Cancer;2024-01